231 related articles for article (PubMed ID: 34815394)
1. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.
Schmelz K; Toedling J; Huska M; Cwikla MC; Kruetzfeldt LM; Proba J; Ambros PF; Ambros IM; Boral S; Lodrini M; Chen CY; Burkert M; Guergen D; Szymansky A; Astrahantseff K; Kuenkele A; Haase K; Fischer M; Deubzer HE; Hertwig F; Hundsdoerfer P; Henssen AG; Schwarz RF; Schulte JH; Eggert A
Nat Commun; 2021 Nov; 12(1):6804. PubMed ID: 34815394
[TBL] [Abstract][Full Text] [Related]
2. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
3. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
5. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
6. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.
Silvestri M; Dugo M; Vismara M; De Cecco L; Lanzoni D; Vingiani A; Folli S; De Santis MC; de Braud F; Pruneri G; Di Cosimo S; Cappelletti V
Sci Rep; 2022 Jan; 12(1):1470. PubMed ID: 35087134
[TBL] [Abstract][Full Text] [Related]
7. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D; Abbosh P; Keliher D; Reardon B; Miao D; Mouw K; Weiner-Taylor A; Wankowicz S; Han G; Teo MY; Cipolla C; Kim J; Iyer G; Al-Ahmadie H; Dulaimi E; Chen DYT; Alpaugh RK; Hoffman-Censits J; Garraway LA; Getz G; Carter SL; Bellmunt J; Plimack ER; Rosenberg JE; Van Allen EM
Nat Commun; 2017 Dec; 8(1):2193. PubMed ID: 29259186
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors.
Zobel M; Zamora A; Sura A; Wang L; Stein J; Marachelian A; Kim ES
J Surg Res; 2020 May; 249():8-12. PubMed ID: 31918331
[TBL] [Abstract][Full Text] [Related]
10. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
[TBL] [Abstract][Full Text] [Related]
11. Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state.
Lundberg G; Jin Y; Sehic D; Øra I; Versteeg R; Gisselsson D
PLoS One; 2013; 8(3):e59268. PubMed ID: 23555645
[TBL] [Abstract][Full Text] [Related]
12. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
[TBL] [Abstract][Full Text] [Related]
13. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
Elife; 2020 May; 9():. PubMed ID: 32401198
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
[TBL] [Abstract][Full Text] [Related]
16. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
17. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
[TBL] [Abstract][Full Text] [Related]
18. Cancer evolution, mutations, and clonal selection in relapse neuroblastoma.
Schulte M; Köster J; Rahmann S; Schramm A
Cell Tissue Res; 2018 May; 372(2):263-268. PubMed ID: 29478075
[TBL] [Abstract][Full Text] [Related]
19. Emergence of new ALK mutations at relapse of neuroblastoma.
Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
[TBL] [Abstract][Full Text] [Related]
20. Frequency and Prognostic Impact of
Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]